Trial Profile
A Phase I Trial Evaluating the Effects of Plerixafor (AMD3100) and G-CSF in Combination With Azacitidine (Vidaza) for the Treatment of MDS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Filgrastim (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Plerixafor (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 01 Jun 2021 Results published in the Leukemia and Lymphoma
- 16 Mar 2017 Status changed from active, no longer recruiting to completed.
- 13 Jun 2016 Planned End Date changed from 1 Mar 2014 to 1 Mar 2017.